Antigenics Inc primarily operates in the biotechnology and pharmaceutical industries.

The main competitors of Antigenics Inc in the market are other companies in the biotechnology industry such as Progenics Pharmaceuticals, Inc., Agenus Inc., and Celldex Therapeutics, Inc.

Antigenics Inc., now known as Agenus Inc., is a biotechnology company that focuses on the discovery, development, and commercialization of immunotherapies for the treatment of cancer and other diseases. Founded in 1994, Antigenics Inc. has a rich history of advancing innovative and personalized therapies that harness the power of the immune system. Over the years, the company has made significant contributions to the field of immuno-oncology and has built a strong portfolio of proprietary platforms and technologies. Antigenics Inc., now Agenus, continues to strive towards developing breakthrough treatments and improving patient outcomes in the fight against cancer.

Antigenics Inc has achieved several significant milestones over the years. One notable accomplishment is the FDA approval of their therapeutic vaccine, Oncophage, in 2010. This vaccine is designed to stimulate the body's immune response against cancer cells, offering a personalized treatment approach for each patient. Additionally, Antigenics Inc has successfully conducted clinical trials, demonstrated positive results, and developed a strong intellectual property portfolio. These achievements highlight the company's dedication to advancing immunotherapies and their commitment to improving patient outcomes in the field of oncology.

Antigenics Inc is primarily present in the United States.

Antigenics Inc represents a strong commitment to advancing innovative immunotherapies. With a focus on developing personalized treatment options, the company aims to address the unmet medical needs of patients. Antigenics Inc values scientific excellence and collaboration to drive groundbreaking research and development initiatives. By leveraging cutting-edge technologies and strategic partnerships, the company strives to improve patient outcomes and enhance quality of life. Emphasizing a patient-centric approach, Antigenics Inc is dedicated to providing hope and solutions for those affected by serious diseases.

Converted at the current exchange rate, the Antigenics share trades at 0,00 EUR (0,00 USD).

Antigenics Inc. is a biotechnology company specializing in the development and commercialization of immunotherapies for cancer and infectious diseases. The company is based in New York City and has offices in Europe and Asia. Antigenics Inc. specializes in the development of individualized immunotherapies for patients with advanced cancer. The company has a proprietary platform technology called A-Ox-HPV, which is based on the use of heat-inactivated Staphylococcus aureus (HISA). This technology allows for the development of personalized cancer vaccines for each patient, containing specific antigenic proteins of the tumor. Antigenics Inc. has conducted Phase II clinical trials for various types of cancer, including lung cancer, colorectal cancer, and prostate cancer. Antigenics Inc. has also developed a unique platform technology called QS-21, which can be used as an adjuvant for a variety of vaccines. QS-21 enhances the ability of the immune system to respond to a range of antigens. Antigenics has sublicensed this technology to other biotech and pharmaceutical companies. In addition to immunotherapies for cancer, Antigenics Inc. has also developed a range of products for the diagnosis and treatment of infectious diseases. The company has granted CEL-SCI Corporation exclusive license rights to use the HISA technology for the production of vaccines for infectious diseases such as Ebola and MERS-CoV. Antigenics Inc. also operates a business unit called AgroBioSciences, which specializes in the development of technologies for agriculture. This business unit uses the QS-21 technology to develop vaccines for livestock and plants. Antigenics Inc.'s business model is based on the development and commercialization of immunotherapies for cancer and infectious diseases, as well as the licensing of its platform technologies to other biotech and pharmaceutical companies. The company generates revenue from conducting clinical trials, selling products, and licensing its technologies. Antigenics Inc. is an innovative biotechnology company specializing in the development of individualized immunotherapies for cancer and infectious diseases. The company has a promising pipeline of immunotherapy candidates and platform technologies that allow it to maximize the potential of its products and have a significant impact on healthcare.

Liikevaihtoa ei voida laskea Antigenics:lle tällä hetkellä.

Voittoa ei voida laskea Antigenics:lle tällä hetkellä.

P/E-suhdetta ei voida laskea Antigenics:lle tällä hetkellä.

P/S-suhdetta ei voida laskea Antigenics:lle tällä hetkellä.

Antigenics:n Eulpool-laatuscore on 4/10.

Antigenics:n ISIN on US0370311013. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Antigenics:n WKN on 932075. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Antigenics:n ticker on ANTI. Tämä pörssinoteeraus käytetään Antigenics-osakkeiden kauppaan pörssissä.

Antigenics maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Antigenics kuuluu sektoriin '—'.

Antigenics:n osingot jaetaan valuutassa USD.